0000000000365359

AUTHOR

Cinzia Caroti

showing 3 related works from this author

Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study.

2012

ABSTRACT Background Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC. Patients and methods This retrospective, multicenter, observational study of 264 patients with CRC involving bone examined cancer treatments, bone metastases characteristics, skeletal-related event (SRE) type and frequency, zoledronic acid therapy, and disease outcomes. Results Most patients with bone metastases had pathologic T3/4 disease at CRC diagnosis. The spine was the most common site involved (65%), followed by hip/pelvis (34%), long bones (26%), and other sites (17%). Median time from CRC diagnosis to b…

Oncologymedicine.medical_specialtyBone Density Conservation AgentSettore MED/06 - Oncologia MedicaColorectal cancerBone NeoplasmsColorectal NeoplasmBone Neoplasmdrug therapy/pathologyZoledronic AcidInternal medicinemedicineHumansImidazolePelvisRetrospective Studiesdrug therapy/secondarybone metastases colorectal cancer zoledronic acidBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesBone metastasisCancerRetrospective cohort studyHematologymedicine.diseaseNatural historyBone Density Conservation AgentsZoledronic acidmedicine.anatomical_structureDiphosphonateOncologytherapeutic useBone Density Conservation Agents; therapeutic use; Bone Neoplasms; drug therapy/secondary; Colorectal Neoplasms; drug therapy/pathology; Diphosphonates; Humans; Imidazoles; Retrospective StudiesbusinessColorectal NeoplasmsHumanmedicine.drug
researchProduct

Receptor activator of NF-kB (RANK) expression associates with bone metastasis in breast carcinomas.

2010

Oncologymedicine.medical_specialtyHistologyPhysiologyActivator (genetics)business.industryEndocrinology Diabetes and MetabolismInternal medicinemedicineBone metastasisbusinessmedicine.diseaseReceptorBone
researchProduct

Receptor Activator of NF-kB (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients

2011

Background\ud Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG.\ud \ud Materials and Methods\ud We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and surviv…

Anatomy and PhysiologyMicroarraysSettore MED/06 - Oncologia MedicaCancer TreatmentLigandsMetastasisBone remodelingMetastasisBasic Cancer ResearchBreast TumorsBone and Soft Tissue SarcomasNeoplasm MetastasisMusculoskeletal SystemOligonucleotide Array Sequence AnalysisMultidisciplinaryPredictive markerReceptor Activator of Nuclear Factor-kappa BQRBone metastasisMiddle AgedImmunohistochemistryGene Expression Regulation NeoplasticOncologyRANKLMedicineFemaleResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyHistologyScienceBone NeoplasmsBreast NeoplasmsBiologyBreast cancerAntibody TherapySDG 3 - Good Health and Well-beingOsteoprotegerinInternal medicinemedicineHumansRNA MessengerBoneBiologyAgedBreast cancer bone metastasis RANK-RANKLRANK LigandOsteoprotegerinComputational BiologyCancers and NeoplasmsRANK Ligandmedicine.diseaseEndocrinologyCancer researchbiology.protein
researchProduct